Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone
about
Charting a Path to Success in Virtual ScreeningExpanding the number of 'druggable' targets: non-enzymes and protein-protein interactionsLeveraging structure determination with fragment screening for infectious disease drug targets: MECP synthase from Burkholderia pseudomalleiUsing a Fragment-Based Approach To Target Protein-Protein InteractionsOvercoming the Limitations of Fragment Merging: Rescuing a Strained Merged Fragment Series TargetingMycobacterium tuberculosisCYP121Fragment screening using capillary electrophoresis (CEfrag) for hit identification of heat shock protein 90 ATPase inhibitorsSubstrate Deconstruction and the Nonadditivity of Enzyme RecognitionIdentification, design and bio-evaluation of novel Hsp90 inhibitors by ligand-based virtual screeningExploring the Trypanosoma brucei Hsp83 potential as a target for structure guided drug designrDock: a fast, versatile and open source program for docking ligands to proteins and nucleic acidsCreating novel activated factor XI inhibitors through fragment based lead generation and structure aided drug designPredicting Allosteric Effects from Orthosteric Binding in Hsp90-Ligand Interactions: Implications for Fragment-Based Drug DesignThe quiet renaissance of protein nuclear magnetic resonance.Heat shock protein 90 inhibition: rationale and clinical potential.Fragment screening of infectious disease targets in a structural genomics environmentDesign of a fragment library that maximally represents available chemical space.The benefits of constructing leads from fragment hits.Protein chaperones: a composition of matter review (2008 - 2013).Thermodynamics of aryl-dihydroxyphenyl-thiadiazole binding to human Hsp90Protein crystallography and fragment-based drug design.Hsp90 molecular chaperone inhibitors: are we there yet?Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment.HSP90 activity is required for MLKL oligomerisation and membrane translocation and the induction of necroptotic cell death.Binding-affinity predictions of HSP90 in the D3R Grand Challenge 2015 with docking, MM/GBSA, QM/MM, and free-energy simulations.Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010.Fragment informatics and computational fragment-based drug design: an overview and update.Discovery of small molecule cancer drugs: successes, challenges and opportunities.Apoptosis and molecular targeting therapy in cancer.Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series.Hsp90 inhibitor NVP-AUY922 enhances radiation sensitivity of tumor cell lines under hypoxia.Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction.Irradiation facilitates the inhibitory effect of the heat shock protein 90 inhibitor NVP-BEP800 on the proliferation of malignant glioblastoma cells through attenuation of the upregulation of heat shock protein 70.POVME 3.0: Software for Mapping Binding Pocket Flexibility.Fragment docking supported by NMR shift perturbations.When Does Chemical Elaboration Induce a Ligand To Change Its Binding Mode?Dynamic undocking and the quasi-bound state as tools for drug discovery.DockBench as docking selector tool: the lesson learned from D3R Grand Challenge 2015.
P2860
Q26779035-AB1129E7-551E-443E-85DC-D467D870C6F0Q27003966-FBE19BA5-6E50-4EBE-99B9-EECC140CEACDQ27667103-A1480B72-2CC6-45AF-A9A6-579C90513371Q27675981-3901A498-6A44-4046-B40F-F1C3CFC962A2Q27678718-2732AF1A-A652-4525-BD4D-B98616E93790Q27678993-52001955-97D4-4928-82F3-560819C3F6D7Q27683622-20618C94-BD9C-40C6-B473-99DE0C217CA3Q28485925-8AEDE08E-EA63-4AFE-A359-1898563F7895Q28534499-A41969FF-5AD3-42AE-8353-158EC75FE926Q28537716-BE8D8944-CFF5-46B0-A0DD-43BE737B84F0Q28543133-A3F66532-D3D7-4F17-B2D1-7FDB60A4D1D0Q28552587-284B7AEB-825D-45BA-83D7-1065AF7F8B37Q30414687-CB117C44-BFAC-4782-9F2F-F5D2C50EA409Q30418761-85315294-668C-4646-9AA8-7766BFEEB449Q33836468-2E7C569C-E736-42B7-94F2-C2865157C404Q33972623-E82DC1B4-408A-4A97-8819-716C2516456BQ33977454-6C85382E-79B7-40B3-BB3A-E2F631C662F7Q34013266-13A02833-28B0-47F9-8799-17CC85BBF63DQ34288879-25F7316A-6A6D-40D8-B668-BD72A0A28DC2Q34353117-761648AA-3182-4428-820C-5F1C22A0BE8FQ35655105-EFAE908A-A22B-4B61-8A23-E3E0055E5106Q35800838-4E770613-2F29-41EC-8FBC-AE9889D56992Q36751725-2E231EE6-3616-4F65-9797-E11BFDE5CFD1Q37363075-2388E7B0-2FDC-4BCF-A218-E92BDA51FF39Q37891987-CAB54DFA-5F4C-4C7B-A23A-F56849349B89Q37995087-C0748AE3-ADEB-48C0-90FD-D41A89D26F59Q37996113-7ABE9AC0-2858-42E2-9842-91B934D3938FQ38228349-3D4BC883-85A2-4C4E-BC60-CFD8AE3E0E0BQ38735183-800A16C6-1544-4855-88FA-9C47455EE2D5Q39404697-913BBF00-6FA1-43CC-9EEF-BB482E1568AAQ39700328-9D64D90D-4FD3-4163-AD7B-8A4C53136C4CQ41827236-8A977A4E-F18F-4F14-ACA6-84BCA297D4B8Q46066890-FE084377-E8AD-48BE-BA19-1309B19DCD9EQ46405437-934CAB37-B385-4972-8F52-936B33C0F817Q48145820-DF9E478F-618E-4051-8933-56A2B106B046Q48213832-892B79C7-17E3-44F2-80D9-62D594ABA671Q48280219-1147CD6B-29F5-4F2B-B59A-96F755D4F414
P2860
Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Combining hit identification s ...... the Hsp90 molecular chaperone
@ast
Combining hit identification s ...... the Hsp90 molecular chaperone
@en
Combining hit identification s ...... the Hsp90 molecular chaperone
@en-gb
Combining hit identification s ...... the Hsp90 molecular chaperone
@nl
type
label
Combining hit identification s ...... the Hsp90 molecular chaperone
@ast
Combining hit identification s ...... the Hsp90 molecular chaperone
@en
Combining hit identification s ...... the Hsp90 molecular chaperone
@en-gb
Combining hit identification s ...... the Hsp90 molecular chaperone
@nl
prefLabel
Combining hit identification s ...... the Hsp90 molecular chaperone
@ast
Combining hit identification s ...... the Hsp90 molecular chaperone
@en
Combining hit identification s ...... the Hsp90 molecular chaperone
@en-gb
Combining hit identification s ...... the Hsp90 molecular chaperone
@nl
P2093
P50
P3181
P356
P1476
Combining hit identification s ...... the Hsp90 molecular chaperone
@en
P2093
Alan Robertson
Allan M Jordan
Allan Surgenor
Angela Hayes
Angela Merrett
Antony Padfield
Brian Dymock
Christophe Fromont
Florence I Raynaud
P304
P3181
P356
10.1021/JM900357Y
P407
P50
P577
2009-08-13T00:00:00Z